183 related articles for article (PubMed ID: 22461474)
1. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.
Foon KA; Mehta D; Lentzsch S; Kropf P; Marks S; Lenzner D; Pietragallo L; Sulecki M; Tarhini A; Boyiadzis M
Blood; 2012 Mar; 119(13):3184-5. PubMed ID: 22461474
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
[TBL] [Abstract][Full Text] [Related]
3. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
[TBL] [Abstract][Full Text] [Related]
4. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
Strati P; Wierda W; Burger J; Ferrajoli A; Tam C; Lerner S; Keating MJ; O'Brien S
Cancer; 2013 Nov; 119(21):3805-11. PubMed ID: 23943357
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
6. [Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab].
Tsukasaki K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():632-5. PubMed ID: 25831837
[No Abstract] [Full Text] [Related]
7. Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.
Bouvet E; Borel C; Obéric L; Compaci G; Cazin B; Michallet AS; Laurent G; Ysebaert L
Haematologica; 2013 Jan; 98(1):65-70. PubMed ID: 23065520
[TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
[TBL] [Abstract][Full Text] [Related]
9. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Lin KI; Tam CS; Keating MJ; Wierda WG; O'Brien S; Lerner S; Coombes KR; Schlette E; Ferrajoli A; Barron LL; Kipps TJ; Rassenti L; Faderl S; Kantarjian H; Abruzzo LV
Blood; 2009 Apr; 113(14):3168-71. PubMed ID: 19050308
[TBL] [Abstract][Full Text] [Related]
10. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.
Fink AM; Böttcher S; Ritgen M; Fischer K; Pflug N; Eichhorst B; Wendtner CM; Winkler D; Bühler A; Zenz T; Staib P; Mayer J; Hensel M; Hopfinger G; Wenger M; Fingerle-Rowson G; Döhner H; Kneba M; Stilgenbauer S; Busch R; Hallek M
Leukemia; 2013 Sep; 27(9):1949-52. PubMed ID: 23787395
[No Abstract] [Full Text] [Related]
11. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
12. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
13. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
[TBL] [Abstract][Full Text] [Related]
15. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Schlette EJ; Admirand J; Wierda W; Abruzzo L; Lin KI; O'Brien S; Lerner S; Keating MJ; Tam C
Leuk Lymphoma; 2009 Oct; 50(10):1597-605. PubMed ID: 19863337
[TBL] [Abstract][Full Text] [Related]
16. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
Herold T; Seiler T; Egensperger R; Trumm C; Bergmann M; Franke D; Mumm FF; Schinwald N; Buske C; Dreyling M
Leuk Lymphoma; 2012 Jan; 53(1):169-72. PubMed ID: 21812535
[No Abstract] [Full Text] [Related]
18. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
19. Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
Marchand T; Revest M; Tattevin P; Chevrier S; Poullot E; Lamy T; Houot R
Leuk Lymphoma; 2013 Mar; 54(3):643-5. PubMed ID: 22924391
[No Abstract] [Full Text] [Related]
20. Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
Feugier P; Aurran T; Mahé B; Letestu R; Nguyen-Khac F; Cazin B; Tournilhac O; Maisonneuve H; Casasnovas O; Delmer A; Leblond V; Royer B; Corront B; Chevret S; Delépine R; Vaudaux S; Van Den Neste E; Béné MC; Cymbalista F; Ross-Weil D; Leprêtre S
Haematologica; 2018 Jul; 103(7):e304-e306. PubMed ID: 29545348
[No Abstract] [Full Text] [Related]
[Next] [New Search]
